https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/cannabidiol-trial-shows-reduction-seizures-children-dravet-syndrome/
Cannabidiol trial shows reduction in seizures for children with Dravet syndrome
30 May 2017, 12:58 p.m.
A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.
The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.
In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.
The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.
Read the press release.
Mystery of treatment resistant childhood leukaemia uncovered
Discovery of a new cancer cell type could enable testing to predict treatment-resistant blood cancer in children with a certain type of leukaemia.
New Director Designate announced for NIHR GOSH Biomedical Research Centre
Professor Paul Gissen has been announced as the Director Designate of the NIHR GOSH Biomedical Research Centre.
Study linking data from 85% of children in England compares rare cardiac risks post-COVID vs vaccination
A major study which analysed anonymised health records from over 14 million children in England has shown that rare heart and inflammatory issues were more likely - and lasted longer - after COVID-19 infection than after vaccination.
Celebrating research that transforms lives
The 2025 NIHR GOSH BRC Showcase recently celebrated some incredible progress made in paediatric research.